Highest-materiality recent filing
Zeo ScientifiX Q1 FY2026 revenue up 124.6% to $2.58M; net loss narrows to ~$1.0M
Revenue for quarter ended Apr 30, 2026: $2.58M vs $1.15M a year ago, +124.6%.
Fully vested options for 625,000 shares each to Greyt Ventures (consultant/stockholder), CEO Ian Bothwell, and CMO George Shapiro; exercise price $1.67, 10-year term.
ZEO ScientifiX monthly sales top $1M in April 2026 for first time
Unaudited single-month sales surpassed $1.0 million in April 2026, a company first.
ZEO named official regenerative medicine educational partner for A4M; Masterclass Apr 9
Role as official educational partner for regenerative medicine with A4M at Longevity SpringFest 2026.
Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law
Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).
Dr. Peter Everts resigns as Chief Scientific & Technology Officer, effective Aug 1, 2025
Dr. Peter A. M. Everts, Ph.D. resigned as Chief Scientific and Technology Officer.
ZEO ScientifiX launches expansion initiative following Florida's new stem cell law
Florida's SB-1768, effective July 1, 2025, authorizes non-FDA-approved stem cell therapies for defined conditions.
ZEO ScientifiX and Exotropin launch ZEO HAIR GROW hair growth system at MAP meeting
ZEO HAIR GROW Powered By Exotropin, a multipart hair growth system, to be introduced at MAP meeting Nov 14-16, 2024 in Scottsdale.
Zeo ScientifiX grants 700K warrants to controlling stockholders and 550K options to insiders
Warrants for 350,000 shares each granted to Skycrest Holdings and Greyt Ventures; exercise price $2.35.
Closed private financing of $500,000 with a single accredited investor on July 8, 2024.
Zeo ScientifiX loses CEO and CSO; CFO Bothwell named interim CEO
CEO Dr. Harry Leider and CSO Dr. Howard Golub employment not renewed; both left May 31, 2024.
Reverse split at 1:200 ratio effective close of business Nov 27, 2023; trading on post-split basis begins Nov 28 under ticker OCELD for 20 days.
Organicell settles with former directors; recovers 232.8M shares
Settlement with Albert Mitrani and Dr. Maria Ines Mitrani resolves Florida state action claims.
Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024
No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.
Organicell appoints Howard Golub as EVP/CSO; 30+ years in clinical therapeutics
Howard L. Golub, MD, PhD appointed EVP and Chief Science Officer effective June 29, 2023.
Organicell appoints Harry Leider, MD, MBA as CEO effective June 21, 2023
Dr. Leider most recently served as CMO/EVP at Gelesis, gaining FDA approval for Plenity and leading the company through a NYSE IPO.
Complaint filed June 7, 2023 in Broward County, Florida, alleging breach of contract, fiduciary duty, tortious interference.
Organicell appoints Harry Leider as CEO and Howard Golub as CSO; Chairman Modi resigns
Dr. Bhupendra Kumar Modi stepped down as Chairman and director on June 4, 2023.
Effective April 1, 2025, Ron Borsheim was appointed the Company’s Chief Sales Officer - Aesthetics.
Effective February 7, 2025, Dr. Peter A. M. Everts, Ph.D. (“ Dr. Everts” ) was appointed the Company’s Chief Scientific and Technology Officer.
Dr. Leider no longer serves as a director of ZEO, as provided for therein.
the employment agreements expired and the employment of Drs. Leider and Golub by the Company ended on May 31, 2024.
the employment agreements expired and the employment of Drs. Leider and Golub by the Company ended on May 31, 2024.
Effective June 1, 2024, our board of directors appointed Ian T. Bothwell, the Company’s Chief Financial Officer to serve in the additional position of Interim Chief Executive Officer
On July 11, 2023, Dr. Maria Ines Mitrani resigned as a director of the Company.
On June 6, 2023, our board of directors appointed Harry Leider, M.D., M.B.A., as Chief Executive Officer and a member of the board of directors
and Howard J. Golub, M.D., as Executive Vice President and Chief Science Officer.
On June 4, 2023, Dr. Bhupendra Kumar Modi stepped down as Chairman of the Board and a director of Organicell.
On May 12, 2023, Organicell terminated Albert Mitrani as its Executive Vice President of Sales and contemporaneously terminated his employment agreement with the Company.
On April 28, 2023, Organicell terminated Dr. Maria Ines Mitrani as its Chief Scientific Officer and contemporaneously terminated her employment agreement with the Company.
Max materiality 0.75 · Median 0.50 · Most common event other_material